Evidence map›Paper›PMID 39000061›Full record

ArticleInternational journal of molecular sciences2024

Molecular Origins of the Mendelian Rare Diseases Reviewed by Orpha.net: A Structural Bioinformatics Investigation.

Anna Visibelli, Rebecca Finetti, Neri Niccolai, Ottavia Spiga, Annalisa Santucci

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anna VisibelliDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.ORCID 0000-0001-9281-034X
Rebecca FinettiDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.ORCID 0009-0000-6969-1493
Neri NiccolaiDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.
Ottavia SpigaDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.ORCID 0000-0002-0263-7107
Annalisa SantucciDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.ORCID 0000-0001-6976-9086

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study of rare diseases is important not only for the individuals affected but also for the advancement of medical knowledge and a deeper understanding of human biology and genetics. The wide repertoire of structural information now available from reliable and accurate prediction methods provides the opportunity to investigate the molecular origins of most of the rare diseases reviewed in the Orpha.net database. Thus, it has been possible to analyze the topology of the pathogenic missense variants found in the 2515 proteins involved in Mendelian rare diseases (MRDs), which form the database for our structural bioinformatics study. The amino acid substitutions responsible for MRDs showed different mutation site distributions at different three-dimensional protein depths. We then highlighted the depth-dependent effects of pathogenic variants for the 20,061 pathogenic variants that are present in our database. The results of this structural bioinformatics investigation are relevant, as they provide additional clues to mitigate the damage caused by MRD.

Indexed as

Computational BiologyRare DiseasesAmino Acid SubstitutionDatabases, GeneticHumansModels, MolecularMutation, MissenseProtein ConformationProteinsProteinsdatabank analysismissense pathogenic variantsprotein structurerare diseasesstructural bioinformatics

Identifiers

PMID39000061
PMCPMC11241713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.